Bioceres Crop Solutions Corp Financials

BIOX

FY2025 annual

Revenue $335.1M -27.9% YoY

Net Income -$58.8M -907.3% YoY

EPS (Diluted) Not reported for FY2025

Free Cash Flow $44.3M +38.6% YoY

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE June

Bioceres Crop Solutions Corp (BIOX) reported $335.1M in revenue for fiscal year 2025, down 27.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BIOX FY2025 2026-08-15

FY2025 cash generation came from releasing working capital, while profitability and short-term liquidity weakened as the business contracted.

The striking FY2025 mismatch was positive cash flow alongside a net loss: operating cash flow reached $49.9M even as net income fell to -$58.8M. That gap points to a working-capital unwind rather than stronger underlying earnings, because receivables and inventory fell by roughly $80M from FY2024, turning balance-sheet shrinkage into cash.

Liquidity tightened at the short end: the current ratio slipped to 0.9x in FY2025, so near-term obligations now exceeded near-term assets. At the same time, long-term leverage stayed light with debt-to-equity at 0.03x and long-term debt of $9.5M, suggesting the funding pressure sits more in working capital than in heavy term borrowing.

FY2024 to FY2025 looks less like a cash collapse than an earnings-quality split: free cash flow improved from $31.9M to $44.3M while revenue fell. Lower capital spending helped, but the bigger message is that cash generation was tied to balance-sheet release, which is not the same thing as recurring margin strength.

Financial Health Signals

Financial Health Score 29/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bioceres Crop Solutions Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Bioceres Crop Solutions Corp, and counted as zero in the overall score.

Growth

Bioceres Crop Solutions Corp's revenue declined 27.9% year-over-year, from $464.8M to $335.1M. This contraction results in a growth score of 10/100.

Leverage

Bioceres Crop Solutions Corp carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Bioceres Crop Solutions Corp's current ratio of 0.91 is below the typical benchmark, resulting in a score of 16/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Bioceres Crop Solutions Corp has a free cash flow margin of 13.2%, earning a moderate score of 62/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Not available for Bioceres Crop Solutions Corp, and counted as zero in the overall score.

Piotroski F-Score Partial

2/8

Bioceres Crop Solutions Corp passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Mixed

N/A

Bioceres Crop Solutions Corp reported a net loss of $58.8M while generating $49.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$335.1M

YoY-27.9%

5Y CAGR+14.1%

Bioceres Crop Solutions Corp generated $335.1M in revenue in fiscal year 2025. This represents a decrease of 27.9% from the prior year.

Net Income

-$58.8M

YoY-907.3%

Bioceres Crop Solutions Corp reported -$58.8M in net income in fiscal year 2025. This represents a decrease of 907.3% from the prior year.

EBITDA

Not reported for fiscal year 2025.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

$44.3M

YoY+38.6%

5Y CAGR+42.0%

Bioceres Crop Solutions Corp generated $44.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 38.6% from the prior year.

Cash & Debt

$32.7M

YoY-26.5%

5Y CAGR-5.1%

Bioceres Crop Solutions Corp held $32.7M in cash against $9.5M in long-term debt as of fiscal year 2025, with $338.0M of liabilities due within a year.

Shares Outstanding

63M

YoY+0.6%

Bioceres Crop Solutions Corp had 63M shares outstanding in fiscal year 2025. This represents an increase of 0.6% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Net Margin

-17.6%

YoY-19.1pp

5Y CAGR-20.0pp

Bioceres Crop Solutions Corp's net profit margin was -17.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 19.1 percentage points from the prior year.

Return on Equity

-19.9%

YoY-22.0pp

5Y CAGR-26.9pp

Bioceres Crop Solutions Corp's ROE was -19.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 22.0 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Capital Allocation

Capital Expenditures

$5.6M

YoY-42.4%

5Y CAGR+27.9%

Bioceres Crop Solutions Corp invested $5.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 42.4% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

BIOX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BIOX annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16
Revenue	$294.4M	$335.1M-27.9%	$464.8M+10.6%	$420.1M+25.4%	$334.8M+59.8%	$209.5M+21.0%	$173.1M+7.8%	$160.6M+20.3%	$133.5M	$41.2M
Interest Expense	N/A	N/A	N/A	N/A	-$25.8M+7.3%	-$27.9M+14.8%	-$32.7M+21.1%	-$41.5M-1.2%	-$41.0M	-$8.2M
Income Tax	$7.1M	$1.3M-66.3%	$3.8M+453.6%	-$1.1M-105.9%	$18.0M+25.2%	$14.4M+550.3%	$2.2M-68.4%	$7.0M+163.9%	-$10.9M	-$1.9M
Net Income	-$243.2M	-$58.8M-907.3%	$7.3M-63.9%	$20.2M+616.1%	-$3.9M-2.3%	-$3.8M-190.2%	$4.2M+125.9%	-$16.4M-14.3%	-$14.3M	-$6.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$73.8M-4.9%	$77.6M-5.9%	$82.4M+36.1%	$60.6M-38.7%	$98.8M+5.9%	$93.3M-24.8%	$124.0M+47.6%	$84.0M
Interest Expense	-$8.0M+12.8%	-$9.1M	N/A	-$6.1M+5.0%	-$6.4M+10.2%	-$7.2M	N/A	-$7.2M
Income Tax	$3.1M+49.3%	$2.1M-64.8%	$5.9M+247.5%	-$4.0M-729.7%	$636K+150.2%	-$1.3M+68.6%	-$4.0M-321.4%	-$956K
Net Income	-$182.5M-2349.8%	-$7.4M+85.6%	-$51.7M-3147.0%	-$1.6M-362.9%	$605K+109.8%	-$6.2M-491.2%	-$1.0M-110.7%	$9.8M
EPS (Diluted)	-$0.08	N/A	N/A	N/A	$0.10	N/A	N/A	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

No annual filing on record for: FY2017.

BIOX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BIOX annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16
Total Assets	$763.6M-10.4%	$852.5M+4.2%	$818.1M+57.9%	$518.2M+31.3%	$394.6M+32.6%	$297.6M+22.7%	$242.5M+23.3%	$196.6M	N/A
Current Assets	$308.3M-24.6%	$408.7M+2.9%	$397.1M+33.4%	$297.7M+40.8%	$211.5M+28.4%	$164.7M+67.7%	$98.2M+15.1%	$85.3M	N/A
Cash & Equivalents	$32.7M-26.5%	$44.5M-7.6%	$48.1M+43.8%	$33.5M-7.1%	$36.0M-15.2%	$42.5M+1132.2%	$3.5M+55.8%	$2.2M	N/A
Inventory	$87.6M-30.4%	$125.9M-10.3%	$140.4M+11.4%	$126.0M+106.5%	$61.0M+108.0%	$29.3M+7.4%	$27.3M+41.1%	$19.4M	N/A
Accounts Receivable	$165.9M-20.0%	$207.3M+31.2%	$158.0M+41.4%	$111.8M+25.9%	$88.8M+20.7%	$73.5M+24.2%	$59.2M+12.0%	$52.9M	N/A
Goodwill	$112.2M0.0%	$112.2M0.0%	$112.2M+210.9%	$36.1M+25.5%	$28.8M+12.6%	$25.5M-14.4%	$29.8M+106.4%	$14.4M	N/A
Total Liabilities	$468.4M-6.5%	$501.2M+2.8%	$487.6M+35.5%	$359.9M+18.3%	$304.3M+28.5%	$236.8M+31.3%	$180.4M+10.3%	$163.5M	N/A
Current Liabilities	$338.0M+2.6%	$329.3M+10.2%	$298.7M+34.2%	$222.7M+32.5%	$168.0M+28.7%	$130.6M+12.2%	$116.5M-1.9%	$118.7M	N/A
Long-Term Debt	$9.5M+16.7%	$8.2M-18.6%	$10.0M-3.0%	$10.3M+2548.1%	$390K-12.2%	$445K-33.1%	$665K	N/A	N/A
Total Equity	$295.2M-16.0%	$351.4M+6.3%	$330.5M+108.8%	$158.3M+75.3%	$90.3M+48.6%	$60.7M-2.2%	$62.1M+87.4%	$33.1M	$83.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$560.4M-23.7%	$734.9M-3.8%	$763.6M-4.3%	$798.2M-4.4%	$835.2M+1.0%	$827.3M-3.0%	$852.5M+2.0%	$836.1M
Current Assets	$294.3M+3.9%	$283.2M-8.2%	$308.3M-8.8%	$338.2M-11.6%	$382.6M+1.5%	$377.1M-7.7%	$408.7M+0.4%	$407.2M
Cash & Equivalents	$11.1M-28.6%	$15.5M-52.6%	$32.7M-15.0%	$38.5M+31.8%	$29.2M-9.6%	$32.3M-27.4%	$44.5M+171.8%	$16.4M
Inventory	$64.8M-26.9%	$88.6M+1.1%	$87.6M-4.8%	$92.0M-9.6%	$101.8M-13.5%	$117.7M-6.6%	$125.9M-2.5%	$129.2M
Accounts Receivable	N/A	$158.4M-4.5%	$165.9M-11.5%	$187.5M-17.2%	$226.5M+15.7%	$195.8M-5.6%	$207.3M-1.8%	$211.2M
Goodwill	$36.1M-67.8%	$112.2M0.0%	$112.2M0.0%	$112.2M0.0%	$112.2M0.0%	$112.2M0.0%	$112.2M0.0%	$112.2M
Total Liabilities	$453.7M+1.6%	$446.5M-4.7%	$468.4M+3.4%	$453.2M-7.3%	$488.9M+1.6%	$481.2M-4.0%	$501.2M+2.8%	$487.6M
Current Liabilities	$328.6M+9.6%	$299.7M-11.3%	$338.0M+1.7%	$332.3M+15.1%	$288.8M-2.4%	$295.9M-10.2%	$329.3M-1.1%	$333.0M
Long-Term Debt	$8.1M-36.4%	$12.8M+34.0%	$9.5M-12.6%	$10.9M+0.4%	$10.8M-30.2%	$15.5M+90.4%	$8.2M-7.2%	$8.8M
Total Equity	$106.6M-63.0%	$288.3M-2.3%	$295.2M-14.4%	$345.0M-0.4%	$346.3M+0.1%	$346.0M-1.5%	$351.4M+0.8%	$348.5M

Not reported in any period shown, so not listed: Retained Earnings.

No annual filing on record for: FY2017.

BIOX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BIOX annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16
Operating Cash Flow	$81.9M	$49.9M+19.6%	$41.7M+1511.4%	$2.6M+114.8%	-$17.5M-182.2%	-$6.2M-166.6%	$9.3M-68.6%	$29.7M+61.5%	$18.4M	-$1.2M
Capital Expenditures	$3.5M	$5.6M-42.4%	$9.8M-13.8%	$11.4M+228.5%	$3.5M+23.3%	$2.8M+70.4%	$1.6M-19.4%	$2.0M-26.8%	$2.8M	$608K
Free Cash Flow	$78.3M	$44.3M+38.6%	$31.9M+464.0%	-$8.8M+58.2%	-$21.0M-132.7%	-$9.0M-217.5%	$7.7M-72.3%	$27.7M+77.3%	$15.6M	-$1.8M
Investing Cash Flow	-$5.1M	-$6.1M+78.7%	-$28.7M-11.7%	-$25.7M-986.2%	$2.9M+134.9%	-$8.3M-6.5%	-$7.8M-139.3%	-$3.3M+60.3%	-$8.2M	-$41.9M
Financing Cash Flow	-$85.1M	-$50.7M-404.2%	-$10.1M-130.5%	$33.0M+122.3%	$14.8M+101.5%	$7.4M-78.1%	$33.5M+224.4%	-$26.9M-157.7%	-$10.5M	$44.0M
Dividends Paid	N/A	$72K-58.8%	$175K-61.3%	$452K	N/A	N/A	N/A	N/A	N/A	$14K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$17.4M+20.9%	$14.4M-46.3%	$26.8M+14.7%	$23.3M+535.6%	-$5.4M-203.9%	$5.2M-77.8%	$23.3M+233.7%	-$17.4M
Capital Expenditures	-$12K-98.1%	$672K+56.1%	$431K-82.2%	$2.4M+59.2%	$1.5M+18.7%	$1.3M-36.6%	$2.0M+18.4%	$1.7M
Free Cash Flow	$17.4M+26.8%	$13.7M-48.0%	$26.3M+25.9%	$20.9M+404.3%	-$6.9M-277.3%	$3.9M-81.7%	$21.2M+211.2%	-$19.1M
Investing Cash Flow	-$2.8M-121.8%	-$1.3M-185.0%	$1.5M+159.4%	-$2.5M+53.5%	-$5.4M-2081.6%	$272K+192.1%	-$295K+78.5%	-$1.4M
Financing Cash Flow	-$18.0M+37.3%	-$28.7M-11.7%	-$25.7M-102.7%	-$12.7M-295.6%	$6.5M+134.5%	-$18.8M-453.3%	$5.3M-51.2%	$10.9M
Dividends Paid	N/A	N/A	$0	$0	N/A	N/A	$0-100.0%	$23K

Not reported in any period shown, so not listed: Share Buybacks.

No annual filing on record for: FY2017.

BIOX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BIOX annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16
Net Margin	-17.6%-19.1pp	1.6%-3.2pp	4.8%+6.0pp	-1.2%+0.7pp	-1.8%-4.3pp	2.5%+12.6pp	-10.2%+0.5pp	-10.7%	-15.0%
Return on Equity	-19.9%-22.0pp	2.1%-4.0pp	6.1%+8.6pp	-2.5%+1.8pp	-4.2%-11.2pp	7.0%+33.3pp	-26.3%+16.8pp	-43.2%	-7.4%
Return on Assets	-7.7%-8.6pp	0.9%-1.6pp	2.5%+3.2pp	-0.8%+0.2pp	-1.0%-2.4pp	1.4%+8.2pp	-6.8%+0.5pp	-7.3%	N/A
Current Ratio	0.91-0.3x	1.24-0.1x	1.330.0x	1.34+0.1x	1.260.0x	1.26+0.4x	0.84+0.1x	0.72	N/A
Debt-to-Equity	0.030.0x	0.020.0x	0.030.0x	0.07+0.1x	0.000.0x	0.010.0x	0.01-4.9x	4.93	N/A
FCF Margin	13.2%+6.3pp	6.9%+9.0pp	-2.1%+4.2pp	-6.3%-2.0pp	-4.3%-8.7pp	4.4%-12.8pp	17.2%+5.5pp	11.7%	-4.5%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Net Margin	-247.2%	-9.6%+53.1pp	-62.7%-60.0pp	-2.6%-3.2pp	0.6%+7.2pp	-6.6%-5.8pp	-0.9%-12.5pp	11.6%
Return on Equity	-171.2%-168.6pp	-2.6%+14.9pp	-17.5%-17.0pp	-0.5%-0.6pp	0.2%+2.0pp	-1.8%-1.5pp	-0.3%-3.1pp	2.8%
Return on Assets	-32.6%-31.6pp	-1.0%+5.8pp	-6.8%-6.6pp	-0.2%-0.3pp	0.1%+0.8pp	-0.8%-0.6pp	-0.1%-1.3pp	1.2%
Current Ratio	0.900.0x	0.940.0x	0.91-0.1x	1.02-0.3x	1.32+0.1x	1.270.0x	1.240.0x	1.22
Debt-to-Equity	0.080.0x	0.040.0x	0.030.0x	0.030.0x	0.030.0x	0.040.0x	0.020.0x	0.03
FCF Margin	23.5%+5.9pp	17.7%-14.3pp	31.9%-2.6pp	34.5%+41.5pp	-7.0%-11.1pp	4.2%-13.0pp	17.1%+39.9pp	-22.7%

Not reported in any period shown, so not listed: Gross Margin, Operating Margin.

No annual filing on record for: FY2017.

Note: The current ratio is below 1.0 (0.91), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Lavoro Limited LVRO

$35.0M

American Vanguard Corp AVD

$65.8M

Intrepid Potash Inc IPI

$492.5M

Enlightify Inc ENFY

$5.8M

Origin Agritech SEED

$12.9M

Where Bioceres Crop Solutions Corp Ranks

Frequently Asked Questions

What is Bioceres Crop Solutions Corp's annual revenue?

Bioceres Crop Solutions Corp (BIOX) reported $335.1M in total revenue for fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bioceres Crop Solutions Corp's revenue growing?

Bioceres Crop Solutions Corp (BIOX) revenue declined by 27.9% year-over-year, from $464.8M to $335.1M in fiscal year 2025.

Is Bioceres Crop Solutions Corp profitable?

No, Bioceres Crop Solutions Corp (BIOX) reported a net income of -$58.8M in fiscal year 2025, with a net profit margin of -17.6%.

How much debt does Bioceres Crop Solutions Corp have?

As of fiscal year 2025, Bioceres Crop Solutions Corp (BIOX) had $32.7M in cash and equivalents against $9.5M in long-term debt.

What is Bioceres Crop Solutions Corp's net profit margin?

Bioceres Crop Solutions Corp (BIOX) had a net profit margin of -17.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bioceres Crop Solutions Corp's return on equity (ROE)?

Bioceres Crop Solutions Corp (BIOX) has a return on equity of -19.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bioceres Crop Solutions Corp's free cash flow?

Bioceres Crop Solutions Corp (BIOX) generated $44.3M in free cash flow during fiscal year 2025. This represents a 38.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bioceres Crop Solutions Corp's operating cash flow?

Bioceres Crop Solutions Corp (BIOX) generated $49.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bioceres Crop Solutions Corp's total assets?

Bioceres Crop Solutions Corp (BIOX) had $763.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bioceres Crop Solutions Corp's capital expenditures?

Bioceres Crop Solutions Corp (BIOX) invested $5.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Bioceres Crop Solutions Corp have outstanding?

Bioceres Crop Solutions Corp (BIOX) had 63M shares outstanding as of fiscal year 2025.

What is Bioceres Crop Solutions Corp's current ratio?

Bioceres Crop Solutions Corp (BIOX) had a current ratio of 0.91 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Bioceres Crop Solutions Corp's debt-to-equity ratio?

Bioceres Crop Solutions Corp (BIOX) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bioceres Crop Solutions Corp's return on assets (ROA)?

Bioceres Crop Solutions Corp (BIOX) had a return on assets of -7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bioceres Crop Solutions Corp's Piotroski F-Score?

Bioceres Crop Solutions Corp (BIOX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bioceres Crop Solutions Corp's earnings high quality?

Bioceres Crop Solutions Corp (BIOX) reported a net loss of $58.8M while generating $49.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bioceres Crop Solutions Corp?

Bioceres Crop Solutions Corp (BIOX) scores 29 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.